Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
October 01, 2021 11:52 ET
|
Novartis Pharma AG
Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has...
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
September 19, 2021 07:30 ET
|
Novartis Pharma AG
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced...
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
September 17, 2021 07:30 ET
|
Novartis Pharma AG
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks,...
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
September 16, 2021 18:05 ET
|
Novartis Pharma AG
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive...
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
August 31, 2021 19:01 ET
|
Novartis Pharma AG
Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three...
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
August 30, 2021 01:15 ET
|
Novartis Pharma AG
New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety...
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
August 03, 2021 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will...
Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.
July 21, 2021 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21%...
Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées
July 21, 2021 01:00 ET
|
Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de...
Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert
July 21, 2021 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +9% (kWk¹, +14% USD): Die Geschäftseinheit Pharmaceuticals legte +12% (kWk, +18% USD) zu mit weiterhin starken...